Quetiapine, an atypical antipsychotic medication used to treat schizophrenia, bipolar disorder, and major depressive disorder (as an adjunct therapy), was developed in the 1990s and approved for medical use in 1997. Its history is marked by its effectiveness in managing both psychotic symptoms and mood instability, making it widely used in psychiatric practice. Quetiapine works by modulating neurotransmitter activity in the brain, particularly dopamine and serotonin receptors, which helps stabilize mood, reduce hallucinations, and improve thought disorders.
Quetiapine was approved in multiple countries and became part of standard treatment regimens for several psychiatric conditions. It is available in immediate-release and extended-release formulations, allowing flexible dosing based on patient needs. Over time, it has also been studied for off-label uses such as insomnia and anxiety disorders, although such use requires careful medical supervision due to potential side effects like sedation, weight gain, and metabolic changes.
BRAND NAMES
Seroquel: Used for immediate-release tablets.
Seroquel XR: Used for extended-release tablets.
MECHANISM OF ACTION
Quetiapine is an atypical antipsychotic that works by modulating neurotransmitter activity in the brain, mainly dopamine and serotonin pathways. It acts as an antagonist at D2 dopamine receptors and 5-HT2A serotonin receptors, which helps reduce psychotic symptoms such as hallucinations, delusions, and disorganized thinking. Its active metabolite, norquetiapine, also contributes by inhibiting norepinephrine reuptake and interacting with multiple receptor systems, supporting antidepressant and mood-stabilizing effects.
PHARMACOKINETICS
Absorption:
Quetiapine is rapidly absorbed after oral administration, with peak plasma levels typically reached within 1–2 hours (immediate-release form). Food may slightly delay absorption but does not significantly affect overall bioavailability.
Distribution:
The drug is widely distributed in body tissues. It is highly protein-bound (about 83%) and crosses the blood-brain barrier to exert its central nervous system effects.
Metabolism:
Quetiapine is extensively metabolized in the liver, mainly by the CYP3A4 enzyme system, producing active and inactive metabolites, including norquetiapine.
Elimination:
It is primarily eliminated through urine (as metabolites) and to a lesser extent in feces. The elimination half-life is approximately 6 hours for the immediate-release formulation.
PHARMACODYNAMICS
Quetiapine produces its therapeutic effects by blocking dopamine D2 and serotonin 5-HT2A receptors, helping to balance neurotransmission in the brain. It also interacts with histamine H1 receptors (causing sedation) and alpha-1 adrenergic receptors (leading to blood pressure lowering effects). These combined actions contribute to its antipsychotic, mood-stabilizing, and sedative properties. The drug is effective in schizophrenia, bipolar disorder (mania and depression phases), and as adjunct therapy in major depressive disorder.
ADMINISTRATION
Quetiapine is administered orally in tablet form, available as immediate-release (taken 2–3 times daily) or extended-release (once daily). Dosing is individualized based on the condition being treated, patient response, and tolerability. It may be taken with or without food, and doses are usually started low and gradually increased to reduce side effects such as sedation and dizziness.
DOSAGE AND STRENGTH
Quetiapine is available in strengths including 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg tablets. For schizophrenia and bipolar disorder, dosing typically ranges from 150 mg to 800 mg per day depending on clinical response. The extended-release form is usually taken once daily, while the immediate-release form is divided into multiple doses throughout the day.
DRUG INTERACTIONS
Quetiapine is primarily metabolized by CYP3A4, so drugs that inhibit or induce this enzyme can significantly affect its levels. Strong CYP3A4 inhibitors such as ketoconazole or certain macrolide antibiotics can increase quetiapine concentration, while inducers like carbamazepine may reduce its effectiveness. Caution is required when used with other central nervous system depressants due to increased sedation risk.
FOOD INTERACTIONS
Food has minimal effect on quetiapine absorption, though taking it with food may slightly delay peak concentration. Grapefruit products may increase drug levels by inhibiting CYP3A4 metabolism and should generally be avoided.
CONTRAINDICATIONS
Quetiapine is contraindicated in patients with known hypersensitivity to the drug or its components. Caution is required in individuals with cardiovascular disease, history of seizures, or conditions predisposing to hypotension or metabolic disorders.
SIDE EFFECTS
Common side effects include:
Drowsiness or sedation
Dizziness
Weight gain
Dry mouth
Orthostatic hypotension
Increased blood glucose and lipid levels
OVER DOSAGE
Overdose of quetiapine most commonly leads to excessive central nervous system depression, with symptoms such as severe drowsiness, sedation, dizziness, confusion, and in serious cases coma. Cardiovascular effects may also occur, including hypotension (low blood pressure), tachycardia (rapid heart rate), and QT interval prolongation, which can increase the risk of cardiac arrhythmias.
TOXICITY
Quetiapine overdose can lead to severe sedation, low blood pressure, rapid heart rate, and in extreme cases, coma. Toxicity is mainly related to central nervous system depression and cardiovascular effects. Management is supportive, including airway protection, cardiac monitoring, and symptomatic treatment. No specific antidote is available.
